What are the main side effects of Melanocortin Receptor Peptides?

Melanocortin Receptor Peptides side effects and warning signals include Nausea (most common, 40% of patients), Flushing, Injection site reactions, Headache, and Transient blood pressure increase.

What evidence level is Melanocortin Receptor Peptides?

Melanocortin Receptor Peptides is rated Level D; the listed research status is Early Research.

Sexual Health / Level D / Early Research / Last reviewed 2026-04-04

Melanocortin Receptor Peptides Evidence Guide

Evidence for Melanocortin Receptor Peptides (as a class of early research tool compounds) is too preliminary to support a research protocol with confidence. These are pharmacological tools for receptor characterization, not therapeutic candidates at this stage. For sexual health applications targeting the melanocortin system, bremelanotide (PT-141) is FDA-approved and is the appropriate clinical reference.

Our Take

Best for: Melanocortin receptor pharmacology research, receptor subtype selectivity studies
Evidence grade: Level D
Confidence: Low
Starting point: No established human therapeutic protocol - tool compounds for receptor research only

Benefits and Evidence

Female Sexual Desire (Bremelanotide): Level A, includes human evidence - Phase III trials (RECONNECT) demonstrated statistically significant increases in sexual desire and reductions in distress related to low desire in premenopausal women with HSDD. FDA approved bremelanotide (Vyleesi) in 2019.
MC4R-Based Obesity Research: Level C, includes human evidence - Setmelanotide (MC4R agonist) is FDA-approved for rare genetic obesity syndromes (POMC, PCSK1, LEPR deficiency). Broader MC4R agonist research for common obesity has been limited by cardiovascular side effects.
Anti-Inflammatory (MC System): Level D, mostly non-human evidence - Getting et al. (2003, Blood) showed the MC3R agonist [D-TRP8]-gamma-MSH reduced inflammatory cell infiltration by 60% and TNF-alpha levels by 45% in murine zymosan peritonitis; Leoni et al. (2008, J Leukoc Biol) demonstrated alpha-MSH analog protection against LPS-induced acute lung injury in mice at 1 mg/kg IP.

Side Effects and Warnings

Nausea (most common, 40% of patients)
Flushing
Injection site reactions
Headache
Transient blood pressure increase
Skin hyperpigmentation with repeated use
Darkening of gums and face
Bremelanotide is contraindicated in uncontrolled hypertension

Research Dosage References

<strong>Subcutaneous (bremelanotide/Vyleesi)</strong> - 1.75 mg - As needed, at least 45 min before anticipated sexual activity - FDA-approved dosing for premenopausal HSDD. Maximum one dose per 24 hours, maximum 8 doses per month. Auto-injector pen.
<strong>Subcutaneous (setmelanotide)</strong> - 1-3 mg daily - Once daily - FDA-approved for rare genetic obesity (POMC, PCSK1, LEPR deficiency). Dose titrated based on response. Not approved for general obesity.

Mechanism of Action

Melanocortin peptides activate specific MC receptor subtypes: 1. MC3R/MC4R activation (sexual function): Bremelanotide activates MC3R and MC4R in the hypothalamus and limbic system, stimulating dopamine release in the mesolimbic pathway and enhancing sexual desire through central arousal mechanisms. 2. MC4R-mediated appetite regulation: MC4R activation in the paraventricular nucleus reduces food intake. Loss-of-function MC4R mutations are the most common monogenic cause of obesity. 3. MC1R (pigmentation): Activation of MC1R on melanocytes drives eumelanin synthesis (basis of Melanotan I/afamelanotide). 4. MC2R (adrenal): ACTH acting on MC2R stimulates cortisol production (not targeted by current therapeutic peptides). 5. MC5R (exocrine function): Involved in sebaceous gland regulation and pheromone signaling. Least studied receptor subtype.

Legal Status

Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. Setmelanotide (Imcivree) is FDA-approved for rare genetic obesity disorders. Other melanocortin peptides remain investigational. Prescription only. Not controlled substances.

Primary Sources

Bremelanotide for hypoactive sexual desire disorder: RECONNECT randomized clinical trial. Obstetrics & Gynecology, 2019.
The melanocortin system in sexual function: a comprehensive review. Hormones and Behavior, 2007.
Melanocortin 4 receptor agonism for obesity: current landscape and future directions. Journal of Clinical Endocrinology & Metabolism, 2019.